Entera Bio (NASDAQ:ENTX) Issues Quarterly Earnings Results

Entera Bio (NASDAQ:ENTX) issued its earnings results on Friday. The company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02, Zacks reports. The business had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.04 million.

Entera Bio Stock Performance

Shares of NASDAQ ENTX opened at $1.75 on Friday. Entera Bio has a fifty-two week low of $1.41 and a fifty-two week high of $3.35. The stock has a market cap of $62.62 million, a PE ratio of -6.73 and a beta of 1.62. The stock has a fifty day moving average of $2.14 and a 200-day moving average of $2.02.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Entera Bio in a research note on Tuesday, March 18th.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.